Introduction
Parkinson's disease (PD) is a neurodegenerative disorder caused by the degeneration of nigral neurons that provide dopamine to the striatum (Ehringer and Hornykiewicz, 1960) . The still most effective symptomatic therapy is the dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA). Long-term treatment leads to L-DOPA-induced dyskinesia (LID) or involuntary aimless movements (Cotzias et al., 1969) . Loss of dopamine in PD induces complex modifications in signaling, with numerous pathways showing exaggerated responses to dopaminergic stimulation in the dopamine-depleted striatum (Bezard et al., 2001a; Jenner, 2008) . Chronic L-DOPA treatment further distorts the signaling. Existing evidence suggests that supersensitivity of D 1 [dopamine D 1 receptor (D 1 R)] and D 2 dopamine receptors is one of the molecular mechanisms underlying LID (Bezard et al., 2001a; Jenner, 2008) .
Homologous desensitization effectively terminates signaling by G-protein-coupled receptors (GPCR), thereby controlling their activity. In theory, the acute activation of dopamine receptors by their direct agonist should provoke a dramatic modification of their subcellular distribution in neurons, including plasma membrane depletion and internalization in the cytoplasm (Dumartin et al., 1998) . In LID, however, at odds with this predicted behavior, we reported that elevated membrane expression and reduced internalization of D 1 R occurs in the striatum of dyskinetic monkeys (Guigoni et al., 2007) , suggesting that LID are associated with deficiencies in the D 1 R desensitization and trafficking Guigoni et al., 2007) . Interestingly, expression level of the D 3 R in the dorsal motor-related striatum correlates with experimental mouse , rat (Bordet et al., 1997) , and primate (Bézard et al., 2003) analogs of dyskinesia. D 1 R and D 3 R are coexpressed by the striatonigral medium spiny neurons (Le Moine and Bloch, 1996; Ridray et al., 1998) and have recently been shown to directly interact (Fiorentini et al., 2008) through an intramembrane D 1 R-D 3 R cross talk (Marcellino et al., 2008) . Therefore, we hypothesized that the lack of L-DOPA-induced D 1 R internalization may be caused by the concomitant stimulation of both D 1 R and D 3 R by their natural ligand dopamine. We here test this hypothesis in the rat analog of LID, i.e., the L-DOPA-induced abnormal involuntary movements (AIMs) in unilaterally 6-hydroxydopamine (6-OHDA)-lesioned animals (Cenci et al., 1998) , investigating the cellular and subcellular distribution of D 1 R at electron microscopic level in a comprehensive behavioral pharmacological study.
Materials and Methods
Experimental design. Adult male Sprague Dawley rats (Charles River Laboratories), weighing 175-200 g at the beginning of the experiment, were used. They were maintained under standard laboratory conditions. Experiments were performed in accordance with French (87-848, Ministère de l'Agriculture et de la Forêt) and European Economic Community (86-6091 EEC) guidelines for the care of laboratory animals and were approved by the Ethical Committee of Centre National de la Recherche Scientifique, Région Aquitaine.
On day 0 of the protocol (Table 1) , unilateral dopamine deprivation of the striatum was obtained by 6-OHDA (3 g/l; Sigma) injection in the right medial forebrain bundle (2.5 l at anterior-posterior ϭ Ϫ3.7 mm, medial-lateral ϭ ϩ1.7 mm, and dorso-ventral ϭ Ϫ8 mm, relative to bregma) (Meissner et al., 2006; Schuster et al., 2008) in rats pretreated with citalopram (1 mg/kg, i.p.; Sigma), an inhibitor of serotonin reuptake and with desipramine hydrochloride (20 mg/kg, i.p.; Sigma), an inhibitor of noradrenergic reuptake (Torres et al., 2003) . Animals displaying both an impaired stepping test (Olsson et al., 1995; Winkler et al., 2002; Pioli et al., 2008) , measured on days 18 -20 (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material), and a loss of tyrosine hydroxylase-immunopositive fibers in the striatum Ͼ95% (Bezard et al., 2001b; Guigoni et al., 2005) , assessed after completion of all experiments (supplemental Fig. 1 , available at www.jneurosci.org as supplemental material), were retained for final analysis.
From day 21 till day 30, rats were treated once daily with benserazide (15 mg/kg, i.p.; Sigma) and either vehicle (12 rats) or L-DOPA (3 mg/kg, i.p.; Sigma) (65 rats) (Table 1) . This dose of L-DOPA was similar to the ED 50 value used for AIMs induction in rats [3.2 mg/kg plus benserazide (12.5 mg/kg, i.p.)] (Putterman et al., 2007) . In such conditions, L-DOPA induces a gradual development of dyskinetic-like AIMs. On day 29, 21 rats were scored as nondyskinetic (score ϭ 0.71), and 44 rats were scored as dyskinetic (score ϭ 8.3) after observation by a trained investigator as described previously (Meissner et al., 2006; Schuster et al., 2008 Schuster et al., , 2009 ) using a validated rating scale (Cenci et al., 1998; Lundblad et al., 2002 (Mach et al., 2004) together with L-DOPA. Doses were chosen for their respective ability to induce D 1 R internalization (Dumartin et al., 1998) and to reduce dyskinesia severity (Bézard et al., 2003) . AIMs score was rated again during the last 15 min before terminal procedure. All animals were killed 60 min after L-DOPA administration. A total of seven experimental groups was thus considered (Table 1) . Four animals were randomly selected in each group for ultrastructural analysis.
Immunohistochemical detection of D 1 R. D 1 R was detected by immunohistochemistry at the light and electron microscopic level according to previously described and validated procedures (Caillé et al., 1996; Dumartin et al., 1998 ) using a monoclonal antibody raised in rat against a 97 aa sequence corresponding to the C terminus of the human D 1 R (Sigma) (Levey et al., 1993; Hersch et al., 1995) . Chloral hydrateanesthetized (400 mg/kg, i.p., VWR) rats were perfused with 2% paraformaldehyde (PFA)/0.2% glutaraldehyde in 0.1 M phosphate buffer at pH 7.4. Brains were quickly removed, left overnight in 2% PFA at 4°C, and cut into 60-m-thick frontal sections with vibratome. To enhance the penetration of the immunoreagents, the sections were equilibrated in a cryoprotectant solution, freeze-thawed, and stored in PBS with 0.03% sodium azide. For light microscopy observation, tissue sections of striatum were treated by immunoperoxidase technique using the tyramide signal amplification method (New England Nuclear) as described previously (Guigoni et al., 2007) or the avidin-biotin complex revealed by the glucose oxidase-DAB-nickel method (Shu et al., 1988) . For electron microscopy observation, D 1 R was detected by the pre-embedding immunogold technique as described previously (Caillé et al., 1996; Dumartin et al., 1998 Dumartin et al., , 2000 . After immunodetection, the vibratome sections were postfixed, dehydrated, and included in resin (Durcupan ACM; Fluka). Serial ultrathin sections were cut with a Reichert Ultracut S, contrasted with lead citrate and examined with Hitachi H-7650 microscope.
Quantitative analysis of immunogold experiments. Abundance of D 1 R in the different subcellular compartments was analyzed from immunogold-treated sections at the ultrastructural level (Dumartin et al., 1998 (Dumartin et al., , 2000 Guigoni et al., 2007) . The analysis was performed on digital images obtained with a computer linked directly to chargecoupled device camera on the electron microscope at a final magnification of 8000 -12,000 using the MetaMorph software (version 4.6r5; Universal Imaging). The immunogold particles were identified and counted in association with five compartments: plasma membrane, rough endoplasmic reticulum, Golgi apparatus, endosome-like small vesicles (Dumartin et al., 1998) , and multivesicular bodies, which are organelles known as marker of the degradative lysosomal pathway (Bernard et al., 2006; Piper and Katzmann, 2007; Hanyaloglu and von Zastrow, 2008) . The measures were performed on 25 perikarya per animal with four animals per group and expressed as the number of immunoparticles per 100 m of membrane, per 100 m 2 of total cytoplasmic surface and the number of immunoparticles associated with each of the five different subcellular compartments per 100 m 2 of cytoplasmic surface. Statistical analysis. For multiple comparisons, depending on the number of factors, a one-way ANOVA (Kruskal-Wallis test) or a three-way ANOVA were followed, if allowed, by post hoc t tests corrected for multiple comparisons. All data were normally distributed, and significance levels of t test comparisons were adjusted for inequality of variances when appropriate. These analyses were completed using STATA program (Intercooled Stata 9.0; Stata Corporation). A probability level of 5% ( p Ͻ 0.05) was considered statistically significant.
Results
Overall D 1 R distribution in parkinsonian animals D 1 R immunostaining at both light and electron microscopic levels showed typical localization in striatal medium spiny neurons in the vehicle-injected 6-OHDA-lesioned animals ( Fig. 1 ). At the light microscopic level, D 1 R was located mostly at the plasma membrane, whatever group considered, with the noticeable exception of SKF-82958-treated groups, that demonstrated prominent cytoplasmic localization ( Fig. 1 A-E 
On day 30, all animals received the last vehicle injection ϩ/Ϫ L-DOPA. D 3 R antagonist ST 198 was injected 60 min before killing (group 7); D 1 R agonist SKF-82958 was injected 45 min before killing (groups 4, 5, and 6). All animals were killed 60 min after L-DOPA, the last administration.
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. Ultrastructural analysis confirmed that, in vehicleinjected 6-OHDA-lesioned animals (group 1), the majority of immunogold particles were located at the inner side of the plasma membrane (61.2%) of the cell bodies. D 1 R was present in low abundance in cytoplasm (38.8%), restricted mostly to the endoplasmic reticulum (30.1%) and the Golgi apparatus (6.2%) (Fig. 1F) . Quantitative analysis of D 1 R localization at the ultrastructural level in subcellular compartments demonstrated several discrete changes in D 1 R subcellular distribution depending on pharmacological treatments (Figs. 2, 3) .
Dramatic increase of D 1 R at the plasma membrane in lesioned side of rats with AIMs Quantitative analysis at the ultrastructural level demonstrated a dramatic and specific increase in D 1 R immunoreactivity at the plasma membrane in lesioned side of L-DOPA-treated rats with AIMs (group 3) compared with their unlesioned side ( p Ͻ 0.05) (Fig. 2 A) . Such an increase in D 1 R abundance at plasma membrane was significantly different from both the vehicle-injected 6-OHDA-lesioned (group 1; p Ͻ 0.05) and the nondyskinetic L-DOPA-treated 6-OHDA-lesioned rats (group 2; p Ͻ 0.05) (Fig.  2 A) . Indeed, in these two groups, D 1 R abundance at membrane was not modified in lesioned side (Fig. 2 A) . Whatever group considered, D 1 R abundance did not change in cytoplasm and organelles (Fig. 2 B) .
AIMs are associated with high abundance of membranebound D 1 R that retains a relative capability of internalization These data suggested that AIMs are related to a recruitment of D 1 R at membrane, thereby confirming our previous data col- lected in monkeys (Guigoni et al., 2007) . Such aberrant behavior for a GPCR required further pharmacological analysis. We, therefore, tested the ability of the specific D 1 R agonist SKF-82958 to induce homologous desensitization in these L-DOPA-treated animals.
Quantitative analysis of D 1 R localization at the ultrastructural level in lesioned striatum demonstrated several discrete changes in D 1 R subcellular distribution specifically related to presence of L-DOPA-induced AIMs, after chronic L-DOPA treatment associated or not with acute SKF-82958 injection. Total D 1 R immunoreactivity in striatal neurons of dopamine-deprived striatum did not change after L-DOPA (groups 2 and 3) or SKF-82958 alone (group 4) but was increased when both drugs were injected (groups 5 and 6) (Fig. 3B) . As expected, dopamine receptor stimulation by L-DOPA or by SKF-82958 decreased D 1 R immunoreactivity at the plasma membrane in all conditions of stimulation, compared with control benserazide group (group 1), with the noticeable exception of the group with L-DOPA-induced AIMs (group 3) (Fig. 3C) . Indeed, D 1 R abundance at the plasma membrane in animals with L-DOPA-induced AIMs was not decreased, whereas it was in animals without L-DOPA-induced AIMs. Interestingly, SKF-82958 challenge unraveled more subtle differences. Animals of groups 5 and 6 differentiated by their AIMs status prior to SKF-82958 challenge, with group 5 animals presenting no AIMs, whereas group 6 did ( Table 1) . The more dyskinetic they were before SKF-82958, the higher the D 1 R membrane abundance remains compared with group 4 animals that were challenged with SKF-82958 only ( p Ͻ 0.05) (Fig. 3C) . Together, these data suggest that D 1 R in L-DOPA-treated brain retains the ability to internalize at a degree that correlates with occurrence of AIMs (the more AIMs the less forced internalization).
AIMs are also associated with alterations of intraneuronal D 1 R localization and impaired internalization
Analysis of D 1 R within the cytoplasm expectedly not only mirrored the membrane localization but unraveled further disturbances. Indeed, stand-alone or combined treatment with L-DOPA and SKF-82958 increased cytoplasmic D 1 R immunoreactivity in all conditions compared with control benserazide group (group 1), with the noticeable exception of group with L-DOPA-induced AIMs (group 3) (Fig. 3D) . Greater increase was achieved when SKF-82958 was coadministered (Fig. 3D) . Indeed, in the cytoplasm of animals with L-DOPA-induced AIMs, D 1 R did not increase (compared with benserazide group), whereas it was more abundant in animals without L-DOPA-induced AIMs ( p Ͻ 0.05). Interestingly, SKF-82958 challenge unraveled more subtle differences. Animals of groups 5 and 6 differentiated by their AIMs status prior to SKF-82958 challenge, with group 5 animals presenting no AIMs, whereas group 6 did ( Table 1) . The more dyskinetic they were before SKF-82958, the higher the D 1 R cytoplasm abundance increases compared with group 4 animals (that were challenged with SKF-82958 only) and between them ( p Ͻ 0.05) (Fig. 3C) . Detailed counting in several organelles ( Fig. 3D1-D4 ) confirmed these specific differences related to AIMs. The more dyskinetic they were before SKF-82958, the higher the D 1 R abundance is in the endoplasmic reticulum (ϩ29.3%; p Ͻ 0.05) (Fig. 3D1) , the Golgi complex (ϩ88.4%; p Ͻ 0.05) (Fig. 3D2) , the vesicular compartment (ϩ149.5%; p Ͻ 0.05) (Fig. 3D3) , and the multivesicular bodies (ϩ424%; p Ͻ 0.05) (Fig. 3D4 ) . Together, these data suggest that D 1 R in L-DOPA-treated brain (1) does not internalize if further challenged with L-DOPA but (2) display greater internalization when challenged with D 1 R agonist, as D 1 R overall availability has dramatically increased (Fig. 3B) .
Disruption of D 1 R-D 3 R cross talk by D 3 R antagonist normalizes D 1 R membrane-bound abundance in rats with
AIMs D 1 R-positive neurons coexpress D 3 R, which expression levels dramatically increase after L-DOPA treatment in dopaminedepleted dorsal striatum (Bordet et al., 1997; Bézard et al., 2003) . In addition, D 1 R and D 3 R directly interact through an intramembrane cross talk (Marcellino et al., 2008) , suggesting that the natural ligand of those receptor, i.e., dopamine, would coactivate them, whereas receptor-specific ligands would not. We thus hypothesized that the lack of L-DOPA-induced D 1 R internalization in dyskinesia is caused by the concomitant stimulation of both D 1 R and D 3 R. To address that question, we tested the effect of the specific D 3 R antagonist ST 198 (Bézard et al., 2003) coadministered with L-DOPA during D 1 R subcellular distribution in dyskinetic 6-OHDA-lesioned rats. ST198, as well as other specific D 3 R antagonist such as S33084, have been shown to reduce dyskinesia severity in rodent and nonhuman primate analog of Parkinson's disease (Bézard et al., 2003; Visanji et al., 2008) , thereby confirming a class effect. Accordingly, ST198 coadministered with L-DOPA reduced AIMs by 22.1% in the 15 min window of behavioral observation immediately before terminal procedure ( p ϭ 0.07; paired t test of area under curve). The short duration of the observation period required by the experimental design prevented data from reaching statistical significance, but the AIM reduction is in full agreement with the decrease in dyskinesia observed at the same time point with D 3 antagonists (Bézard et al., 2003; Visanji et al., 2008 ) that then develops in statistical significance at later time points. Quantitative analysis at the ultrastructural level demonstrated that coadministration of ST 198 with L-DOPA decreased significantly D 1 R abundance at plasma membrane to a level identical to both the nondyskinetic L-DOPA-treated animals and the vehicle-injected animals ( p Ͻ 0.05) (Fig. 4 A) . No significant modification was observed in the cytoplasm or in organelles after ST 198 injection (Fig. 4 B) . These data suggest that D 3 R anchors D 1 R at membrane in dyskinetic animals.
Discussion
The present data show that AIMs are related to D 1 R overexpression at the plasma membrane associated with intraneuronal trafficking dysregulation including organelles involved in biosynthesis, packaging, and degradation, namely endoplasmic reticulum, Golgi complex, and vesicles. We show that D 1 R retains its ability to internalize as the potent D 1 R agonist SKF-82958 promotes membrane depletion in chronically L-DOPA-treated 6-OHDAlesioned rats, with a magnitude of induced-internalization related to AIMs occurrence prior to SKF-82958 challenge. We further show that this aberrant presence at the plasma membrane of medium spiny neurons is controlled by D 1 R-D 3 R interactions as coadministration of the specific D 3 R antagonist ST 198 with L-DOPA normalizes membrane-bound D 1 R abundance.
AIMs are linked to D 1 R overexpression at plasma membrane Dyskinetic chronically L-DOPA-treated 6-OHDA-lesioned rats showed an overrepresentation of D 1 R at the plasma membrane of striatal medium spiny neurons. On the contrary, denervation alone or combined with a L-DOPA treatment that does not provoke AIMs has no effect on membrane abundance. These data substantiate previous limited information obtained in dyskinetic monkeys showing both an increased D 1 R expression at membrane (Guigoni et al., 2007) and a relative decrease in the protein machinery of the homologous desensitization . The relationship between D 1 R membrane abundance and motor abnormalities fits with the main pathophysiological hypothesis of LID placing D 1 R supersensitivity at the cornerstone of the phenomenon (Bezard et al., 2001a; Jenner, 2008) . Such overexpression at membrane is, however, not exclusive of other mechanisms. Further stimulation using the D 1 R agonist SKF-82958 shows that, if D 1 R does not internalize spontaneously under L-DOPA in dyskinetic animals, it retains the ability to internalize. Such experimental evidence suggests that AIMs are not caused by the inability of D 1 R to internalize, and consequently to desensitize, but rather by its active maintenance at membrane.
…and to D 1 R trafficking dysregulation
Distribution analysis in subcellular compartments shows that specific abnormalities in D 1 R intraneuronal localization are associated with AIMs. These abnormalities are apparent with the sole L-DOPA treatment but are clearly unraveled by SKF-82958 stimulation suggesting that AIMS are associated with a latent dysregulation of D 1 R trafficking. Combined treatment with L-DOPA and SKF-92958 has additive effects resulting into an increase in D 1 R content in all cytoplasmic compartments. In such conditions, the important rise in endoplasmic reticulum, Golgi complex, and vesicular system associated with overexpression of membrane-bound receptor strongly suggest that D 1 R biosynthetic steps, involving translation and packaging, contribute directly to D 1 R supersensitivity. The dyskinetic rats have initially more D 1 R at the membrane. Although D 1 R internalizes under dopamine agonist stimulation, D 1 R is nevertheless more retained at the plasma membrane than in the nondyskinetic rats comparably challenged. The dyskinetic rats also present a greater increase in D 1 R in the endoplasmic reticulum, the Golgi complex, vesicles, and multivesicular bodies under L-DOPA-SKF-82958 association than the nondyskinetic ones. These results are consistent with our previous data showing specific increase in both D 1 R expression and sensitivity in dyskinetic monkeys . A complementary and nonexclusive hypothesis is that AIMs are linked to increased biosynthesis and degradation of D 1 R (compared with the situation in nondyskinetic rats) associated to a lesser sensitivity to homologous desensitization by its natural agonist, dopamine. That this decreased desensitization capability is caused by decreased bioavailability of the protein machinery, e.g., arrestins and GPCR-regulated kinases , or by a modification of the D 1 R, such as receptor oligomerization (Kong et al., 2006) , remains an open question.
Nevertheless, since the electron microscopic detection of cytoplasmic vesicles does not differentiate between endocytic and exocytic vesicles, the important rise of immunogold positive particles in vesicles after L-DOPA-SKF-82958 association may reflect (1) an increased membrane delivery through exocytic vesicles and/or (2) an increased internalization through endocytic vesicles. The dramatic augmentation of multivesicular bodies under L-DOPA-SKF-82958 treatment supports the occurrence of the latter pathway and extends it to increased D 1 R degradation in the cytoplasm after internalization, since multivesicular bodies are markers of the lysosomal pathway (Bernard et al., 2006; Piper and Katzmann, 2007; Hanyaloglu and von Zastrow, 2008 ). An all-inclusive concept might well be that dyskinesia are related to an increased D 1 R turn-over resulting into decreased D 1 R half-life in medium spiny neurons.
A key role for D 3 R in maintaining D 1 R at membrane Since D 1 R and D 3 R directly interact through an intramembrane cross talk (Marcellino et al., 2008) and that the D 1 R-positive neurons coexpress D 3 R (Le Moine and Bloch, 1996; Ridray et al., 1998) , we hypothesized that the lack of L-DOPA-induced D 1 R internalization in dyskinesia is caused by the concomitant stimulation of both D 1 R and D 3 R. The release of D 1 R internalization when using D 3 R antagonist ST 198 in combination with L-DOPA (Fig. 4) firmly substantiates and extends previous pharmacological, behavioral, and anatomical data suggesting functionally relevant important D 3 R-D 1 R interactions in neurons of the dorsal striatum. Although a role for the D 3 R itself in LID pathophysiology has been suggested (Bordet et al., 1997; Bézard et al., 2003) culminating with demonstration that both D 3 R partial agonist and antagonists decrease dyskinesia in primate (Bézard et al., 2003) , the exact mechanism by which modulation of D 3 R activity was affecting medium spiny activity remained shadowy. The existence of a direct intramembrane D 1 R-D 3 R cross talk (Marcellino et al., 2008) offers an explanation both for the previous behavioral data and for the present data. The L-DOPA-derived dopamine would bind to both D 1 R and D 3 R, anchoring D 1 R to membrane in both dyskinetic rats (present data set) and monkeys (Guigoni et al., 2007) , two animal models into which D 3 R is highly increased (Bordet et al., 1997; Bézard et al., 2003) . Antagonizing the D 3 R releases D 1 R from the plasma membrane. Not only this result demonstrates for the first time the physiological (ensuring dopamine receptor availability) and pathophysiological role (too much D 1 R at membrane because of increased D 3 R expression) of the cross talk, but it also provides a mechanistic explanation for the reduction in dyskinesia severity after D 3 R antagonist treatment.
Together, these results further support the hypothesis that D 1 R fate in medium spiny neurons during dyskinesia induction and occurrence is under multiple influences and can be modulated by pharmacological approaches. Further studies are now needed for investigating the offered antidyskinetic therapeutic possibilities by disrupting the dopamine receptor cross talks and/or by modulating D 1 R fate at different levels.
